

May 16, 2023


TO: Rapid Dose Therapeutics Corporation
British Columbia Securities Commission
Alberta Securities Commission
Ontario Securities Commission
Canadian Securities Exchange

Dear Sirs/Madams:

Re: Rapid Dose Therapeutics Corporation (the “Company”)

Pursuant to National Instrument 51-102 Continuous Disclosure Obligations, we have reviewed the information contained in the Notice of Change of Auditor of the Company dated May 16, 2022 (“the Notice”) and, based on our knowledge of such information at this time, we agree with the statements made in the Notice pertaining to MNP LLP.

Yours very truly,



Chartered Professional Accountants
Licensed Public Accountants
Mississauga, Ontario